Thus, inhibition of the JNK signaling is considered to be a protective strategy against the neurodegeneration in AD and PD, and the JNK inhibitor has been proposed as the therapeutic candidate for these diseases [92]. This evidence concerns the gene MAPK8 and Alzheimer disease.